Benjamin Kaplan, MD
Physical Medicine & Rehabilitation · Philadelphia, PANPI 1407267099
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 329 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,192 and has fallen 71.3% since, to $342 in 2025. Among physical medicine & rehabilitation clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 329 payments — averaging $14.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Scilex Pharmaceuticals Inc.$725
- Zyla Life Sciences, Inc.$346
- Biodelivery Sciences International, Inc.$248
- Arbor Pharmaceuticals, Inc.$171
- plus $1K from 23 others
What the payments were for
- Food & beverage$4,894100%
- Gifts$00%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 61 | $1,116 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 93 | $1,036 |
| Scilex Pharmaceuticals Inc. | 37 | $725 |
| Zyla Life Sciences, Inc. | 32 | $346 |
| Biodelivery Sciences International, Inc. | 16 | $248 |
| Arbor Pharmaceuticals, Inc. | 14 | $171 |
| Sentynl Therapeutics, Inc. | 14 | $164 |
| Valinor Pharma, LLC | 8 | $145 |
| Pfizer | 10 | $139 |
| Merck | 7 | $106 |
| Almatica Pharma LLC | 5 | $97 |
| Redhill Biopharma Inc. | 5 | $70 |
| Tonix Medicines, Inc. | 1 | $67 |
| Axonics, Inc. | 1 | $67 |
| Averitas Pharma Inc. | 2 | $44 |
| IBSA Pharma Inc. | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $41 |
| Vertex | 2 | $35 |
| Assertio Therapeutics, Inc. | 2 | $31 |
| Daiichi Sankyo Inc. | 2 | $30 |
| Electronic Waveform Lab, Inc. | 1 | $29 |
| Shionogi Inc | 2 | $28 |
| Amgen | 2 | $28 |
| Virtus Pharmaceuticals LLC | 2 | $27 |
| Pernix Therapeutics Holdings, Inc. | 1 | $14 |
| Forte Bio-pharma LLC | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Hikma Pharmaceuticals USA | 1 | $12 |
| West Therapeutics Development, LLC | 1 | $11 |
How this compares
$4,894 in reported general payments places this provider in the 90th percentile of 550 physical medicine & rehabilitation providers in Pennsylvania.
See all physical medicine & rehabilitation providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PercocetOxycodone Hcl/Acetaminophen | 38 | $163,647 |
| OxycontinOxycodone Hcl | 137 | $135,610 |
| BelbucaBuprenorphine Hcl | 53 | $46,210 |
| Xtampza ErOxycodone Myristate | 48 | $26,184 |
| MovantikNaloxegol Oxalate | 65 | $25,866 |
| Oxycodone Hcl | 820 | $20,345 |
| ZtlidoLidocaine | 22 | $19,104 |
| LinzessLinaclotide | 28 | $14,994 |
| Nucynta ErTapentadol Hcl | 16 | $14,973 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 244 | $8,602 |
| Lidocaine | 92 | $6,620 |
| Fentanyl | 37 | $4,793 |
| Gabapentin | 316 | $3,806 |
| Morphine Sulfate ErMorphine Sulfate | 151 | $3,426 |
| Cyclobenzaprine Hcl | 147 | $2,580 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta Er | $1,116 | $87,367117 claims |
| Redhill Biopharma Inc.Movantik | $70 | $25,86665 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $725 | $19,10422 claims |
| Hikma Pharmaceuticals USAMorphine Sulfate | $12 | $53128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 550 physical medicine & rehabilitation providers in Pennsylvania.
Other physical medicine & rehabilitation in Philadelphia
- Alberto EsquenaziPhiladelphia$305K
- Kimberly HeckertPhiladelphia$119K
- Elaine HatchPhiladelphia$25K
- Benjamin AbramoffPhiladelphia$15K
- Ramesh GuptaPhiladelphia$14K
- Marisa MoretaPhiladelphia$13K
- M Quinn TatePhiladelphia$6K
- Cameron OlezenePhiladelphia$4K
- Jeffery RoweKing Of Prussia$1.9M
- Michael SaulinoElkins Park$425K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.